RESUMO
After actively entering its host cells, the protozoan parasite Toxoplasma gondii resides in an intracellular vacuole that is completely unable to fuse with other endocytic or biosynthetic organelles. The fusion blocking requires entry of viable organisms but is irreversible: fusion competence of the vacuole is not restored if the parasite is killed after entry. The fusion block can be overcome, however, by altering the parasite's route of entry. Thus, phagocytosis of viable antibody-coated T. gondii by Chinese hamster ovary cells transfected with macrophage-lymphocyte Fc receptors results in the formation of vacuoles that are capable of both fusion and acidification. Phagocytosis and fusion appear to involve a domain of the Fc receptor cytoplasmic tail distinct from that required for localization at clathrin-coated pits. These results suggest that the mechanism of fusion inhibition is likely to reflect a modification of the vacuole membrane at the time of its formation, as opposed to the secretion of a soluble inhibitor by the parasite.
Assuntos
Receptores Fc/fisiologia , Toxoplasma/fisiologia , Transfecção , Vacúolos/parasitologia , Animais , Linhagem Celular , Fibroblastos/parasitologia , Fibroblastos/fisiologia , Fibroblastos/ultraestrutura , Imunofluorescência , Lisossomos/fisiologia , Lisossomos/ultraestrutura , Macrófagos/imunologia , Fusão de Membrana , Camundongos , Camundongos Endogâmicos BALB C , Fagocitose , Receptores Fc/genética , Toxoplasma/crescimento & desenvolvimento , Vacúolos/fisiologia , Vacúolos/ultraestruturaRESUMO
Recent studies have revealed that Ras can associate physically with Raf. In the present study, we tested 34 mutants of Ha-Ras carrying substitution(s) in the region of residues 23-71 for their ability to associate with Raf-1. Mouse Ba/F3 cell lysates were incubated with each mutant Ras protein, in either the guanosine 5'-[gamma-thio]triphosphate (GTP gamma S)- or the guanosine 5'-[beta-thio]diphosphate (GDP beta S)-bound form, and the anti-Ras antibody Y13-238. The immunoprecipitates were analysed for the presence of Raf-1 by Western blotting with an anti-Raf-1 antibody. Six mutants of Ras, E31K, P34G, T35S, D38N, D57A and A59T, failed to bind Raf-1. Mutations N26G, V29A, S39A, Y40W, R41A, V44A, V45E, L56A and T58A partially reduced the ability to bind Raf-1. All the other mutants could associate with Raf-1 with nearly the same efficiency as that of wild-type Ras. Thus, the Raf-I-binding ability of Ras appears to be affected by mutations in the N-terminal region, and in particular, by those in and neighboring the effector region (residues 32-40) and in the region (residues 56-59) flanking the N-terminal of Switch II. The abilities to bind Raf-1 and to induce neurite outgrowth of pheochromocytoma (PC) 12 cells correlate to each other for 22 Ras mutants. However, mutation A59T, which does not reduce the neurite-inducing or transforming activities, abolishes the ability to bind Raf-1. In contrast, mutations Y32F, K42A and L53A, which impair the neurite-inducing activity of Ras, have no effect on the Ras.Raf-1 association. Partially reduced Raf-1-binding ability was observed for mutants V29A, S39A, Y40W, R41A, V44A, L56A and T58A, which exhibit full neurite-inducing activity, and also for mutant V45E, which has no activity of neurite induction.
Assuntos
Genes ras , Mutação , Proteínas Serina-Treonina Quinases/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Animais , Células Cultivadas , Guanosina Difosfato/metabolismo , Guanosina Trifosfato/metabolismo , Camundongos , Células PC12 , Proteínas Proto-Oncogênicas c-raf , RatosRESUMO
While mild to moderate hepatic dysfunction is commonly encountered in infectious mononucleosis induced by Epstein-Barr virus (EBV), clinical jaundice with high bilirubin levels (greater than or equal to 6.0 mg/dL [greater than or equal to 103 mumol/L] is only occasionally encountered. In this study, seven patients with primary EBV infections had peak bilirubin levels of 10.2 to 23.0 mg/dL (174 to 393 mumol/L) and, for the most part, presented initial diagnostic problems. Complications included the virus-associated hemophagocytic syndrome and acute respiratory distress syndrome in one patient and transient renal failure in another. The laboratory data suggested that a combination of hemolysis and viral-induced cholestasis was responsible for the intense hyperbilirubinemia in at least five patients. Physicians should be aware that marked hyperbilirubinemia can occur with EBV-induced infectious mononucleosis and, thereby, obviate the need for costly diagnostic laboratory tests and, occasionally, invasive procedures.
Assuntos
Hiperbilirrubinemia/etiologia , Mononucleose Infecciosa/complicações , Adolescente , Adulto , Anticorpos Antivirais/análise , Feminino , Herpesvirus Humano 4/imunologia , Humanos , Imunoglobulina G/análise , Imunoglobulina M/análise , Mononucleose Infecciosa/imunologia , MasculinoRESUMO
The prognostic significance of morphologic parameters was evaluated in 103 patients with renal cell carcinoma diagnosed during 1961--1974. Pathologic material was classified as to pathologic stage, tumor size, cell arrangement, cell type and nuclear grade. Four nuclear grades (1--4) were defined in order of increasing nuclear size, irregularity and nucleolar prominence. Nuclear grade was more effective than each of the other parameters in predicting development of distant metastasis following nephrectomy. Among 45 patients who presented in Stage I, tumors classified as nuclear grade 1 did not metastasize for at least 5 years, whereas 50% of the higher grade tumors did so. Moreover, among Stage I tumors there was a significant difference in subsequent metastatic rate between nuclear grades 1 and 2. There was an apparent positive relationship between cell type and metastatic rate; clear cell tumors were less aggressive than predominantly granular cell tumors (metastatic rate 38% versus 71%). This relationship in part a function of the nuclear grade: only 5% of grade 3 and 4 tumors consisted of clear cells, whereas such high grades were seen in 57% of granular cell tumors. The size of the primary correlated well with the stage at the time of surgery. However, with the exception of extremely large and small tumors, the size was not useful in predicting the subsequent course of patients treated for Stage I tumors. Nuclear grade was the most significant prognostic criterion for the outcome of Stage I renal cell carcinoma.
Assuntos
Adenocarcinoma/patologia , Neoplasias Renais/patologia , Adenocarcinoma/diagnóstico , Adulto , Idoso , Feminino , Humanos , Neoplasias Renais/diagnóstico , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Prognóstico , Veias Renais/patologiaRESUMO
The structure-based design, chemical synthesis, and biological evaluation of various ketomethylene-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and an ethyl propenoate Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. The ketomethylene-containing inhibitors typically display slightly reduced 3CP inhibition activity relative to the corresponding peptide-derived molecules, but they also exhibit significantly improved antiviral properties. Optimization of the ketomethylene-containing compounds is shown to provide several highly active 3C protease inhibitors which function as potent antirhinoviral agents (EC90 = <1 microM) against multiple virus serotypes in cell culture.
Assuntos
Antivirais/síntese química , Cisteína Endopeptidases/metabolismo , Inibidores de Cisteína Proteinase/síntese química , Dipeptídeos/síntese química , Cetonas/síntese química , Rhinovirus/enzimologia , Proteínas Virais , Proteases Virais 3C , Antivirais/química , Antivirais/farmacologia , Linhagem Celular , Inibidores de Cisteína Proteinase/química , Inibidores de Cisteína Proteinase/farmacologia , Dipeptídeos/química , Dipeptídeos/farmacologia , Desenho de Fármacos , Humanos , Cetonas/química , Cetonas/farmacologia , Mimetismo Molecular , Rhinovirus/efeitos dos fármacos , Relação Estrutura-AtividadeRESUMO
The design, synthesis, and biological evaluation of reversible, nonpeptidic inhibitors of human rhinovirus (HRV) 3C protease (3CP) are reported. A novel series of 2,3-dioxindoles (isatins) were designed that utilized a combination of protein structure-based drug design, molecular modeling, and structure-activity relationship (SAR). The C-2 carbonyl of isatin was envisioned to react in the active site of HRV 3CP with the cysteine responsible for catalytic proteolysis, thus forming a stabilized transition state mimic. Molecular-modeling experiments using the apo crystal structure of human rhinovirus-serotype 14 (HRV-14) 3CP and a peptide substrate model allowed us to design recognition features into the P1 and P2 subsites, respectively, from the 5- and 1-positions of isatin. Attempts to optimize recognition properties in the P1 subsite using SAR at the 5-position were performed. In addition, a series of ab initio calculations were carried out on several 5-substituted isatins to investigate the stability of sulfide adducts at C-3. The inhibitors were prepared by general synthetic methods, starting with commercially available 5-substituted isatins in nearly every case. All compounds were tested for inhibition of purified HRV-14 3CP. Compounds 8, 14, and 19 were found to have excellent selectivity for HRV-14 3CP compared to other proteolytic enzymes, including chymotrypsin and cathepsin B. Selected compounds were assayed for antiviral activity against HRV-14-infected HI-HeLa cells. A 2.8 A cocrystal structure of derivative 19 covalently bound to human rhinovirus-serotype 2 (HRV-2) 3CP was solved and revealed that the isatin was situated in essentially the same conformation as modeled.
Assuntos
Cisteína Endopeptidases/efeitos dos fármacos , Inibidores de Proteases/síntese química , Inibidores de Proteases/farmacologia , Proteínas Virais , Proteases Virais 3C , Antivirais/síntese química , Antivirais/química , Antivirais/farmacologia , Cisteína Endopeptidases/química , Células HeLa , Humanos , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Estrutura Molecular , Inibidores de Proteases/química , TermodinâmicaRESUMO
A series of nonpeptide benzamide-containing inhibitors of human rhinovirus (HRV) 3C protease was identified using structure-based design. The design, synthesis, and biological evaluation of these inhibitors are reported. A Michael acceptor was combined with a benzamide core mimicking the P1 recognition element of the natural 3CP substrate. alpha,beta-Unsaturated cinnamate esters irreversibly inhibited the 3CP and displayed antiviral activity (EC(50) 0.60 microM, HRV-16 infected H1-HeLa cells). On the basis of cocrystal structure information, a library of substituted benzamide derivatives was prepared using parallel synthesis on solid support. A 1.9 A cocrystal structure of a benzamide inhibitor in complex with the 3CP revealed a binding mode similar to that initially modeled wherein covalent attachment of the nucleophilic cysteine residue is observed. Unsaturated ketones displayed potent reversible inhibition but were inactive in the cellular antiviral assay and were found to react with nucleophilic thiols such as DTT.
Assuntos
Benzamidas/síntese química , Benzamidas/farmacologia , Cisteína Endopeptidases/efeitos dos fármacos , Inibidores de Cisteína Proteinase/síntese química , Inibidores de Cisteína Proteinase/farmacologia , Rhinovirus/enzimologia , Proteínas Virais , Proteases Virais 3C , Antivirais/síntese química , Antivirais/farmacologia , Cristalografia por Raios X , Cisteína Endopeptidases/química , Desenho de Fármacos , Humanos , Conformação Proteica , Rhinovirus/efeitos dos fármacos , Relação Estrutura-AtividadeRESUMO
The investigation of tripeptide aldehydes as reversible covalent inhibitors of human rhinovirus (HRV) 3C protease (3CP) is reported. Molecular models based on the apo crystal structure of HRV-14 3CP and other trypsin-like serine proteases were constructed to approximate the binding of peptide substrates, generate transition state models of P1-P1' amide cleavage, and propose novel tripeptide aldehydes. Glutaminal derivatives have limitations since they exist predominantly in the cyclic hemiaminal form. Therefore, several isosteric replacements for the P1 carboxamide side chain were designed and incorporated into the tripeptide aldehydes. These compounds were found to be potent inhibitors of purified HRV-14 3CP with Kis ranging from 0.005 to 0.64 microM. Several have low micromolar antiviral activity when tested against HRV-14-infected H1-HeLa cells. The N-acetyl derivative 3 was also shown to be active against HRV serotypes 2, 16, and 89. High-resolution cocrystal structures of HRV-2 3CP, covalently bound to compounds 3, 15, and 16, were solved. These cocrystal structures were analyzed and compared with our original HRV-14 3CP-substrate and inhibitor models.
Assuntos
Antivirais , Cisteína Endopeptidases/metabolismo , Inibidores de Cisteína Proteinase , Desenho de Fármacos , Glutamina/química , Oligopeptídeos , Rhinovirus/efeitos dos fármacos , Proteínas Virais , Proteases Virais 3C , Antivirais/síntese química , Antivirais/química , Antivirais/farmacologia , Sítios de Ligação , Linhagem Celular Transformada , Cristalografia por Raios X , Cisteína Endopeptidases/química , Inibidores de Cisteína Proteinase/síntese química , Inibidores de Cisteína Proteinase/química , Inibidores de Cisteína Proteinase/farmacologia , Células HeLa , Humanos , Modelos Moleculares , Conformação Molecular , Oligopeptídeos/síntese química , Oligopeptídeos/metabolismo , Oligopeptídeos/farmacologia , Conformação Proteica , Rhinovirus/enzimologiaRESUMO
The structure-based design, chemical synthesis, and biological evaluation of peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds incorporate various Michael acceptor moieties and are shown to irreversibly bind to HRV serotype 14 3CP with inhibition activities (kobs/[I]) ranging from 100 to 600 000 M-1 s-1. These inhibitors are also shown to exhibit antiviral activity when tested against HRV-14-infected H1-HeLa cells with EC50's approaching 0.50 microM. Extensive structure-activity relationships developed by Michael acceptor alteration are reported along with the evaluation of several compounds against HRV serotypes other than 14. A 2.0 A crystal structure of a peptide-derived inhibitor complexed with HRV-2 3CP is also detailed.
Assuntos
Antivirais , Cisteína Endopeptidases/metabolismo , Inibidores de Cisteína Proteinase , Desenho de Fármacos , Oligopeptídeos , Rhinovirus/efeitos dos fármacos , Proteínas Virais , Proteases Virais 3C , Animais , Antivirais/síntese química , Antivirais/química , Antivirais/metabolismo , Antivirais/farmacologia , Sítios de Ligação , Linhagem Celular Transformada , Cristalografia por Raios X , Cisteína Endopeptidases/química , Inibidores de Cisteína Proteinase/síntese química , Inibidores de Cisteína Proteinase/química , Inibidores de Cisteína Proteinase/metabolismo , Inibidores de Cisteína Proteinase/farmacologia , Estabilidade de Medicamentos , Células HeLa , Humanos , Oligopeptídeos/síntese química , Oligopeptídeos/química , Oligopeptídeos/metabolismo , Oligopeptídeos/farmacologia , Conformação Proteica , Ratos , Ratos Sprague-Dawley , Rhinovirus/enzimologia , Relação Estrutura-AtividadeRESUMO
The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (kobs/[I]) ranging from 60 to 280 000 M-1 s-1 and antiviral EC50's which approach 0.15 microM. An optimized inhibitor which incorporates several improvements identified by the structure-activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (kobs/[I] = 800 000 M-1 s-1) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 microM). A 1.9 A crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-2 3CP is also detailed.
Assuntos
Antivirais , Cisteína Endopeptidases/metabolismo , Inibidores de Cisteína Proteinase , Desenho de Fármacos , Oligopeptídeos , Rhinovirus/efeitos dos fármacos , Proteínas Virais , Proteases Virais 3C , Antivirais/síntese química , Antivirais/química , Antivirais/metabolismo , Antivirais/farmacologia , Sítios de Ligação , Linhagem Celular Transformada , Cristalografia por Raios X , Cisteína Endopeptidases/química , Inibidores de Cisteína Proteinase/síntese química , Inibidores de Cisteína Proteinase/química , Inibidores de Cisteína Proteinase/metabolismo , Inibidores de Cisteína Proteinase/farmacologia , Avaliação Pré-Clínica de Medicamentos , Humanos , Oligopeptídeos/síntese química , Oligopeptídeos/química , Oligopeptídeos/metabolismo , Oligopeptídeos/farmacologia , Rhinovirus/enzimologia , Relação Estrutura-AtividadeRESUMO
The structure-based design, chemical synthesis, and biological evaluation of various human rhinovirus (HRV) 3C protease (3CP) inhibitors which incorporate P1 lactam moieties in lieu of an L-glutamine residue are described. These compounds are comprised of a tripeptidyl or peptidomimetic binding determinant and an ethyl propenoate Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. The P1-lactam-containing inhibitors display significantly increased 3CP inhibition activity along with improved antirhinoviral properties relative to corresponding L-glutamine-derived molecules. In addition, several lactam-containing compounds exhibit excellent selectivity for HRV 3CP over several other serine and cysteine proteases and are not appreciably degraded by a variety of biological agents. One of the most potent inhibitors (AG7088, mean antirhinoviral EC90 approximately 0.10 microM, n = 46 serotypes) is shown to warrant additional preclinical development to explore its potential for use as an antirhinoviral agent.
Assuntos
Antivirais/síntese química , Cisteína Endopeptidases/metabolismo , Inibidores de Cisteína Proteinase/síntese química , Glutamina/química , Isoxazóis/síntese química , Lactamas/síntese química , Oligopeptídeos/síntese química , Pirrolidinonas/síntese química , Rhinovirus/enzimologia , Proteínas Virais , Proteases Virais 3C , Antivirais/química , Antivirais/farmacologia , Linhagem Celular , Cristalografia por Raios X , Inibidores de Cisteína Proteinase/química , Inibidores de Cisteína Proteinase/farmacologia , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Humanos , Isoxazóis/química , Isoxazóis/farmacologia , Lactamas/química , Lactamas/farmacologia , Modelos Moleculares , Mimetismo Molecular , Oligopeptídeos/química , Oligopeptídeos/farmacologia , Fenilalanina/análogos & derivados , Pirrolidinonas/química , Pirrolidinonas/farmacologia , Rhinovirus/efeitos dos fármacos , Relação Estrutura-Atividade , Valina/análogos & derivadosRESUMO
The wide array of tests available for the diagnosis of Cushing's syndrome can be daunting. This review discusses each test and its role in the diagnosis of patients with this disorder. The discussion is then followed by an algorithm that summarizes the appropriate work-up of Cushing's syndrome.
Assuntos
Síndrome de Cushing/diagnóstico , Adenoma/complicações , Hormônio Adrenocorticotrópico/sangue , Hormônio Liberador da Corticotropina , Síndrome de Cushing/sangue , Síndrome de Cushing/etiologia , Síndrome de Cushing/urina , Dexametasona , Diagnóstico Diferencial , Humanos , Hidrocortisona/sangue , Hidrocortisona/urina , Metirapona , Neoplasias Hipofisárias/complicaçõesRESUMO
The establishment of mobile or portable laboratories as one strategy for delivery of laboratory services at alternative sites is evaluated. The mobile laboratory may be used to replace centralized laboratory testing in areas of critical need, such as critical care areas of the hospital in which relatively large numbers of tests are needed quickly. Other possible areas of use include outpatient clinics and other outreach settings in which care of the patient may be hastened by the availability of laboratory data on a real-time basis. In such areas where a need is established, mobile laboratory testing may be performed economically and may enhance the position of the medical technologist as a hands-on clinical caregiver.
Assuntos
Laboratórios , Unidades Móveis de Saúde , Sistemas Automatizados de Assistência Junto ao Leito , Sistemas de Informação em Laboratório Clínico , Custos de Cuidados de Saúde , Necessidades e Demandas de Serviços de Saúde , Laboratórios/economia , Sistemas Automatizados de Assistência Junto ao Leito/economiaAssuntos
Glândulas Suprarrenais/enzimologia , RNA Polimerases Dirigidas por DNA/metabolismo , Proteínas Quinases/metabolismo , Glândulas Suprarrenais/efeitos dos fármacos , Hormônio Adrenocorticotrópico/farmacologia , Aminoglutetimida/farmacologia , Sulfato de Amônio , Animais , Bucladesina/farmacologia , Cromatografia por Troca Iônica , Cicloeximida/farmacologia , DNA , Feminino , Glucocorticoides/sangue , Cobaias , Hipofisectomia , Radioisótopos de Fósforo , Hipófise/fisiologia , Moldes Genéticos , TrítioRESUMO
Tachyzoites of the obligate intracellular protozoan Toxoplasma gondii are resistant to lysis in non-immune human serum. We have examined the mechanism of this serum resistance in RH and P strain organisms, which differ markedly in virulence, but are equally resistant to serum killing. Rapid, but limited, activation of the alternative complement pathway occurred in non-immune human serum, with deposition of equivalent amounts of C3 on the two strains. C component C3 bound covalently to parasite acceptor molecules via an ester linkage. The predominant form of C3 was iC3b which cannot participate in formation of a lytic C5b-9 complex. Multiple membrane constituents of the tachyzoite of T. gondii may serve as acceptors for the limited amount of C3 deposited during incubation in non-immune serum. When tachyzoites were presensitized with the lytic anti-p30 mAb 7B8, new amide-linked C3-acceptor complexes formed. Nearly equivalent C3 binding but a threefold enhancement of 125I-C9 binding occurred when mAb 7B8 pre-sensitized tachyzoites were compared to native organisms. These results indicate that tachyzoites of T. gondii are serum resistant because of failure to activate C efficiently. Presensitization with a lytic mAb alters the site of complement deposition and augments C5b-9 formation.
Assuntos
Proteínas do Sistema Complemento/fisiologia , Citotoxicidade Imunológica , Imunidade Inata , Toxoplasma/imunologia , Animais , Sangue/imunologia , Sangue/parasitologia , Complemento C3/isolamento & purificação , Complemento C3/metabolismo , Complemento C9/metabolismo , Via Alternativa do Complemento , Proteínas do Sistema Complemento/imunologia , Proteínas do Sistema Complemento/metabolismo , Humanos , Imunização , Antígeno de Macrófago 1 , Receptores de Complemento/análise , Toxoplasma/crescimento & desenvolvimento , Toxoplasma/metabolismoRESUMO
In the presence of 50 mM (NH4)2SO4 and low concentrations of alpha-amanitin (7.7 mug/ml), adrenal nuclei synthesize predominately rRNA as characterized by size and base composition. Approximately 10% of the RNA synthesized under these conditions sediments at 4-5 S; this RNA synthesizing activity is inhibited by high concentrations of alpha-amanitin (231 mug/ml) indicating the presence of RNA polymerase III activity. ACTH administration to guinea pigs results in a twofold increase in adrenal nuclear RNA polymerase I and III activities at 14 hr of hormone treatment. Analysis of the amount of radiolabeled nucleoside triphosphate incorporated in vitro into 3' chain termini and into internal nucleotide positions has been utilized to measure the number of RNA chains and the average chain length synthesized in vitro. Incorporation into 3' chain termini is not changed by ACTH; incorporation into internal nucleotides is doubled in parallel with the increase in RNA polymerase I activity. These results are not due to an altered Km of RNA polymerase I for the four nucleoside triphosphates, nor to differential R Nase or phosphatase activity. These studies suggest that the regulation of RNA polymerase I by ACTH is accomplished in part through an increase in the rate of RNA chain elongation.
Assuntos
Córtex Suprarrenal/metabolismo , Glândulas Suprarrenais/metabolismo , Hormônio Adrenocorticotrópico/farmacologia , RNA Polimerases Dirigidas por DNA/metabolismo , Transcrição Gênica/efeitos dos fármacos , Amanitinas/farmacologia , Animais , Núcleo Celular/efeitos dos fármacos , Centrifugação com Gradiente de Concentração , Nucleotídeos de Citosina/metabolismo , Feminino , Cobaias , Cinética , Peso Molecular , Nucleosídeos/metabolismo , Nucleotídeos/análise , Nucleotídeos/metabolismo , RNA/biossíntese , RNA Ribossômico/biossíntese , Ratos , Estimulação Química , Fatores de Tempo , Nucleotídeos de Uracila/metabolismoRESUMO
In response to the pressures of cost reduction, we established and evaluated a carefully integrated program to deliver clinical laboratory services more promptly and efficiently to the intensive care units (ICUs). The new protocol reduced the steps and turnaround time from ordering tests by physicians to reporting results by as much as 80% on all ICUs, permitting significant reductions in personnel (exceeding $400,000 per year). For the surgical ICU there were also fewer blood collections (mean preprotocol: 7.0 per patient per 24 h; mean last 12 months: 6.0; P= 0.002). The volume of blood collected fell from 8.1 to 3.5 mL per collection, primarily following an emphasis on small containers. Consequently, the amount of blood taken from each surgical ICU patient decreased from 56 to 21 mL per 24 h (P <0.001).
Assuntos
Química Clínica/métodos , Unidades de Terapia Intensiva , Coleta de Amostras Sanguíneas/métodos , Química Clínica/economia , Custos e Análise de Custo , Controle de Formulários e Registros , Humanos , Laboratórios/economia , Fatores de TempoRESUMO
We have used a soluble in vitro RNA polymerase II transcription system to define the site of initiation of Moloney murine leukemia viral RNA synthesis. Molecularly cloned integrated and unintegrated Moloney murine leukemia virus DNAs were used as templates. The 5' ends of in vitro transcripts and virion RNA of Moloney murine leukemia virus were compared by nuclease S1 protection experiments. Our results indicate that viral sequences upstream of the in vivo cap site are implicated in the transcription of viral RNA and that the 5' end of an in vitro transcript derived from an integrated Moloney murine leukemia virus clone corresponds to the 5' end of viral genomic RNA.
Assuntos
DNA Viral/genética , RNA Polimerases Dirigidas por DNA/metabolismo , Vírus da Leucemia Murina de Moloney/genética , RNA Polimerase II/metabolismo , Transcrição Gênica , Sistema Livre de Células , Genes Virais , Óperon , Plasmídeos , RNA Viral/biossíntese , Sequências Repetitivas de Ácido NucleicoRESUMO
That stable transcription complexes are formed in HeLa cell RNA polymerase III transcription extracts (Weil, P. A., Segall, J., Harris, B., Ng, S.-Y., and Roeder, R. G. (1979) J. Biol. Chem. 254, 6163-6173) can be shown in order of template addition experiments with DNAs coding for adenovirus 2 VA I RNA or one of the Bombyx mori tRNAAla2 genes. Using this property of the HeLa extracts in a "second template rescue assay" has allowed us to partially purify protein components involved in stable transcription complex formation. Two fractions, called transcription fraction X (TfrX) and transcription fraction Y (TfrY), are required to fully reconstitute selective transcription of the VA I and tRNAAla2 DNA templates. TfrX contains one or more components required for forming transcriptional pre-emptive complexes, as shown in order of addition experiments. TfrX strongly protects a DNA segment surrounding the highly conserved distal sequence (the so-called B block) of the VA I and tRNAAla2 genes from DNase I digestion; we have also characterized weak protection of other segments of these genes by TfrX. DNase I protection experiments with TfrX and probes prepared from deletion variants of the VA I gene show that an intact B block is required for the strong protection.